Subscribe
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Foundayo significantly reduced obstructive sleep apnea severity, reinforcing its potential to improve health beyond weight loss – Eli Lilly

Written by | 16 Nov 2026 | Conference Highlights

Eli Lilly and Company announced positive results from ATTAIN-OSA, a Phase 3 clinical program evaluating the efficacy and safety of Foundayo (orforglipron) in adults with moderate-to-severe obstructive sleep apnea (OSA) and obesity or overweight, with and without the use of positive airway pressure (PAP) therapy.

At 52 weeks, Foundayo met the primary endpoint, significantly reducing the apnea-hypopnea index (AHI), the standard measure of sleep apnea severity, as well as improving weight and other cardiovascular risk factors. The results were presented at the American Heart Association (AHA) Scientific Sessions 2026 and simultaneously published in JAMA.

OSA affects an estimated 936 million adults worldwide, and most have never been diagnosed. In people with OSA, the airway repeatedly collapses during sleep, causing drops in oxygen and increases in blood pressure that are associated with hypertension, heart failure, atrial fibrillation, coronary artery disease and stroke. The AHA counts healthy sleep among its Life’s Essential 8 measures of cardiovascular health and recommends screening for OSA in people with certain cardiovascular conditions, reflecting growing recognition that treating OSA is part of comprehensive cardiovascular care.

Vaishnavi Kundel, M.D., M.S., Associate Professor of Medicine, Division of Pulmonary, Critical Care and Sleep Medicine, Icahn School of Medicine at Mount Sinai: “We know there’s a two-way relationship between sleep and cardiovascular health, and the repeated drops in oxygen that happen with obstructive sleep apnea can strain blood pressure and the heart over time. In ATTAIN-OSA, Foundayo significantly reduced breathing interruptions and drops in oxygen during sleep, while also improving blood pressure and inflammation. In addition to improving their sleep, what I care about for my patients is improving the cardiovascular risk factors that have the potential to impact long-term health.”

In participants not using PAP therapy, Foundayo reduced the number of AHI events by 21.1 per hour (43.8%) at 52 weeks from an average baseline of 50.7 events per hour. Notably, 47.2% of these participants achieved an AHI reduction of 50% or more, and 31.5% achieved remission or mild disease. In participants using PAP therapy, Foundayo reduced the number of AHI events by 18.3 per hour (27.5%) at 52 weeks from an average baseline of 57.6 events per hour. Of these participants, 33.7% achieved an AHI reduction of 50% or more, and 19.6% achieved remission or mild disease. Foundayo also reduced sleep apnea-specific hypoxic burden, a measure of how deeply and for how long oxygen levels fall during sleep, by 81.4 percent-minutes per hour (55.9%) in participants not using PAP therapy and by 75.0 percent-minutes per hour (45.8%) in those using PAP therapy.

Alongside these improvements in OSA, participants taking Foundayo lost an average of 28.0 lbs (11.5%) and 28.2 lbs (11.2%), without and with PAP therapy, respectively. Foundayo also improved certain cardiovascular risk factors, lowering hsCRP, a marker of inflammation, by an average of 48.9% and 38.6%, and systolic blood pressure by an average of 8.6 mmHg and 7.3 mmHg, in participants not using and using PAP therapy, respectively.

Thomas Seck, M.D., Senior Vice President of Product Development of Lilly Cardiometabolic Health: “OSA is one of the most serious complications of obesity and is closely linked to cardiovascular disease. In ATTAIN-OSA, Foundayo significantly improved sleep apnea along with key cardiovascular risk factors, showing its potential to treat conditions that drive heart disease. Foundayo is already making a difference for people living with obesity, and with plans to submit these results to the FDA by the end of the year, we could have the opportunity to help people living with OSA.”

The overall safety and tolerability profile of Foundayo was generally consistent with previous trials in the ACHIEVE and ATTAIN programs. The most common adverse events were gastrointestinal, including nausea, diarrhea, constipation, dyspepsia and vomiting, and were generally mild to moderate in severity. Discontinuation rates due to adverse events with Foundayo vs. placebo were 12.2% vs. 3.8% among participants not using PAP therapy and 6.8% vs. 0.6% among those using PAP therapy.

Lilly plans to submit Foundayo to the U.S. FDA for the treatment of moderate-to-severe obstructive sleep apnea in adults with obesity or overweight by the end of 2026.

About ATTAIN-OSA
ATTAIN-OSA (NCT06649045) is a Phase 3, 52-week, randomized, multicenter, double-blind, placebo-controlled trial investigating the efficacy and safety of Foundayo maximum tolerated dose (MTD) once daily versus placebo in participants who had moderate-to-severe obstructive sleep apnea (OSA) and obesity or overweight. The trial was comprised of two pivotal, independent studies (Study 1 and Study 2). Study 1 included 363 participants who were unable or unwilling to use PAP therapy; Study 2 included 349 participants who were on PAP therapy for at least 3 months at time of screening and continued PAP therapy during the study. In both studies, participants taking Foundayo started the study at a dose of Foundayo 0.8 mg once-daily and then increased the dose in a step-wise approach at four-week intervals to a maximum tolerated dose of 9 mg (via steps at 0.8 mg, 2.5 mg and 5.5 mg), 14.5 mg (via steps at 0.8 mg, 2.5 mg, 5.5 mg, and 9 mg) or 17.2 mg (via steps at 0.8 mg, 2.5 mg, 5.5 mg, 9 mg and 14.5 mg). The studies were conducted using an investigational formulation of Foundayo at dosages equivalent to Foundayo tablets.

Citation: Orforglipron for Obstructive Sleep ApneaResults From 2 Randomized Clinical Trials (ATTAIN-OSA). Authors: Atul Malhotra, MD; Daniel J. Gottlieb, MD, MPH; Holger Woehrle, MD et al. JAMA Published Online: November 9, 2026. doi: 10.1001/jama.2026.24080

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.

Subscribe

You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.